Pinteon Therapeutics
2014
FOUNDED
PRIVATE
STATUS
Series A
LATEST DEAL TYPE
$10M
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of cancer therapeutics drugs intended to cure cis-trans isomerase. The company's drugs are based out of biotechnological compounds focused on the discovery and development of therapeutics targeting Pin1 and related targets, enabling researchers to normalize aberrant disease processes and improve patient outcomes in these high unmet medical need indications.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 1188 Centre Street
- Newton Centre
- Newton, MA 02459
- United States
+1 (917) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Pinteon Therapeutics’s full profile, request a free trial.
Pinteon Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 17-Aug-2017 | $10M | 0000 | 000.00 | Completed | Startup |
Pinteon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Pinteon Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Morningside Group | PE/Buyout | Minority | 000 0000 | 000000 0 |